Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.71 |
| ▸ | MET | P08581 | 1/20 | 0.67 |
| ▸ | JAK1 | P23458 | 2/20 | 0.67 |
| ▸ | TYK2 | P29597 | 2/20 | 0.67 |
| ▸ | JAK3 | P52333 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142928 | 1.00 | JAK2 (0.71) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL15140258 | 0.89 | ALK (0.62) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL12004170 | 0.89 | MET (0.65) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL2592143 | 0.89 | ALK (0.62) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL24828662 | 0.86 | JAK2 (0.54) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL17310028 | 0.86 | JAK2 (0.54) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL2586716 | 0.86 | ALK (0.64) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL15140053 | 0.86 | ALK (0.64) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL15273940 | 0.86 | JAK2 (0.54) | JAK2METJAK1TYK2JAK3 | |
| SCHEMBL17206245 | 0.85 | MET (0.68) | JAK2METJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119070-B | Selective JAK2 inhibitors and uses thereof | 华东理工大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-115260156-A | Compounds as JAK2 inhibitors and uses thereof | 华东理工大学 | 2022-11-01 | — | — | CN | disclosed |
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3782993-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | East China University of Science and Technology (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782993-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | East China University of Science and Technology (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-112119070-A | Selective JAK2 inhibitor and application thereof | 华东理工大学 | 2020-12-22 | — | — | CN | disclosed |
| CN-108314676-B | Amino pyridine derivative containing hydroxamic acid fragment and anti-tumor application thereof | 上海医药工业研究院 | 2020-07-14 | — | — | CN | disclosed |
| CN-108264500-B | Substituted 2-aminopyridines and preparation method thereof | 正大天晴药业集团股份有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019196937-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012116050-A2 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179598-A1 | SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885MET 708/4885JAK1 2/4885 |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | PPM1A, PPM1G, PPM1B | JAK2 416/4885MET 503/4885JAK1 282/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | JAK2 1124/4885MET 21/4885JAK1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.